MINERALYS THERAPEUTICS, INC. Earnings Per Share (Basic)
MINERALYS THERAPEUTICS, INC. (MLYS) reported Earnings Per Share (Basic) of -$2.85 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$2.85.
- MINERALYS THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.47.
- MINERALYS THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.40.
- MINERALYS THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.52.
- MINERALYS THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$2.29.
- MINERALYS THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$3.66.
- MINERALYS THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$1.99.
- MINERALYS THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$5.77.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.85 10-Q · filed 2026-08-11 | -$3.35 10-Q · filed 2026-08-11 | -$3.77 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$4.38 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.47 10-Q · filed 2026-05-06 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.39 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.02 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.29 10-K · filed 2026-03-12 |
| 2025-09-30 | -$0.52 10-Q · filed 2025-11-10 | -$1.18 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.94 10-Q · filed 2025-11-10 | -$2.87 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.66 10-Q · filed 2026-08-11 | -$1.44 10-Q · filed 2026-08-11 | -$2.39 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.49 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$0.79 10-Q · filed 2026-05-06 | -$1.77 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.89 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.73 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2024-12-31 | -$0.98 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$2.94 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$3.66 10-K · filed 2026-03-12 |
| 2024-09-30 | -$1.13 10-Q · filed 2025-11-10 | -$1.96 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$2.68 10-Q · filed 2025-11-10 | -$3.33 derived: net income ÷ weighted average shares · filed 2025-11-10 |
| 2024-06-30 | -$0.83 10-Q · filed 2025-08-12 | -$1.54 10-Q · filed 2025-08-12 | -$2.16 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$2.75 derived: net income ÷ weighted average shares · filed 2025-11-10 |
| 2024-03-31 | -$0.70 10-Q · filed 2025-05-12 | -$1.31 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$1.89 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$2.20 derived: net income ÷ weighted average shares · filed 2025-11-10 |
| 2023-12-31 | -$0.61 derived: net income ÷ weighted average shares · filed 2025-02-12 | -$1.18 derived: net income ÷ weighted average shares · filed 2025-02-12 | -$1.48 derived: net income ÷ weighted average shares · filed 2025-02-12 | -$1.99 10-K · filed 2025-02-12 |
| 2023-09-30 | -$0.57 10-Q · filed 2024-11-12 | -$0.88 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$1.36 10-Q · filed 2024-11-12 | -$2.06 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-06-30 | -$0.31 10-Q · filed 2024-08-13 | -$0.77 10-Q · filed 2024-08-13 | -$1.46 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$2.16 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-03-31 | -$0.51 10-Q · filed 2024-05-09 | -$1.45 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$2.42 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$3.46 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2022-12-31 | -$1.74 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$3.03 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$4.29 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$5.77 10-K · filed 2024-03-21 |
| 2022-09-30 | -$1.29 10-Q · filed 2023-11-07 | -$2.55 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$4.02 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$1.26 10-Q · filed 2023-08-07 | -$2.73 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$1.48 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |